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Central nervous system primitive neuroectodermal tumours (CNS PNET) are high-grade, predominantly paediatric, brain tumours.
Previously they have been grouped with medulloblastomas owing to their histological similarities. The WNT/b-catenin pathway has
been implicated in many tumour types, including medulloblastoma. On pathway activation b-catenin (CTNNB1) translocates to the
nucleus, where it induces transcription of target genes. It is commonly upregulated in tumours by mutations in the key pathway
components APC and CTNNB1. WNT/b-catenin pathway status was investigated by immunohistochemical analysis of CTNNB1 and
the pathway target cyclin D1 (CCND1) in 49 CNS PNETs and 46 medulloblastomas. The mutational status of APC and CTNNB1
(b-catenin) was investigated in 33 CNS PNETs and 22 medulloblastomas. CTNNB1 nuclear localisation was seen in 36% of CNS
PNETs and 27% of medulloblastomas. A significant correlation was found between CTNNB1 nuclear localisation and CCND1 levels.
Mutations in CTNNB1 were identified in 4% of CNS PNETs and 20% of medulloblastomas. No mutations were identified in APC.
A potential link between the level of nuclear staining and a better prognosis was identified in the CNS PNETs, suggesting that the extent
of pathway activation is linked to outcome. The results suggest that the WNT/b-catenin pathway plays an important role in the
pathogenesis of CNS PNETs. However, activation is not caused by mutations in CTNNB1 or APC in the majority of CNS PNET cases.
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The most common solid tumours during childhood are those of
the central nervous system. Central nervous system primitive
neuroectodermal tumours (CNS PNET) are high-grade embryonal
tumours that occur at any extracerebellar site in the central
nervous system and are composed of undifferentiated or poorly
differentiated neuroepithelial cells (Louis et al, 2007). Currently,
outcome for children with CNS PNET is poor with a relatively low
overall 5-year survival rate (Reddy et al, 2000; Geyer et al, 2005;
Timmermann et al, 2006; Johnston et al, 2008). Relatively little
research has been undertaken to elucidate the molecular basis of
CNS PNETs. Earlier they have often been grouped with the
histologically similar tumour medulloblastoma; both being com-
posed of poorly differentiated round ‘blue’ cells with scant
cytoplasm (Louis et al, 2007). An increased understanding of
CNS PNET biology will allow a more targeted approach to therapy.
Many studies have shown deregulation of developmental
signalling pathways involved in normal brain development in
medulloblastoma. Similar pathways are likely to be involved in
CNS PNETs. The WNT/b-catenin signalling pathway plays a key
role in many cellular functions related to tumourigenesis,
including cell proliferation, differentiation and migration. It was
originally linked to medulloblastoma through studies of Turcot
syndrome, in which germline mutations in the APC gene have been
identified (Hamilton et al, 1995).
b-catenin (CTNNB1) is the key downstream effecter of the
pathway. When the pathway is inactive, CTNNB1 is bound in the
cytoplasm to a complex containing the proteins adenomatous
polyposis coli (APC), axin1 and glycogen synthase kinase-3b
(GSK-3b). Glycogen synthase kinase-3b phosphorylates CTNNB1
at specific serine and threonine residues, allowing the protein to be
targeted for degradation through the ubiquitin–proteosome
system (Morin, 1999). On pathway activation the protein complex
is destabilised, preventing phosphorylation and enabling CTNNB1
to translocate to the nucleus, where it acts as a co-activator of TCF
and LEF transcription factors and leads to the upregulation of
target genes, including MYC and cyclin D1(CCND1)( H eet al, 1998;
Tetsu and McCormick, 1999).
Activating mutations in CTNNB1 have been identified in many
different cancers, including colon, gastric, hepatocellular, prostate
and Wilms’ tumour (Morin et al, 1997; Iwao et al, 1998; Voeller
et al, 1998; Koch et al, 1999; Koesters et al, 1999; Ogasawara et al,
2006). Single base substitutions have been identified at codons, in
exon 3 of the gene, encoding serine and threonine residues
targeted by GSK-3b, or at adjacent residues. These mutations are
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spredicted to prevent phosphorylation and subsequent degradation
of CTNNB1. Pathway activation through the stabilisation and
nuclear accumulation of CTNNB1 has been shown in sporadic
medulloblastomas (Eberhart et al, 2000; Koch et al, 2001; Yokota
et al, 2002; Ellison et al, 2005; Clifford et al, 2006; Gajjar et al, 2006;
Thompson et al, 2006). In the majority of cases this was caused by
activating mutations in CTNNB1. A small study identified a single
mutation in CTNNB1 in one out of four CNS PNETs (Koch et al,
2001). No further research has been undertaken in CNS PNET
to date.
APC is also commonly mutated in many tumour types including
colon and gastric, with the majority of mutations occurring in the
mutation cluster region (Miyoshi et al, 1992; Ogasawara et al,
2006). Mutations in APC are commonly truncating, resulting in
proteins that are not able to form the cytoplasmic complex to
target CTNNB1 for degradation. APC mutations are rare in
sporadic medulloblastomas (Huang et al, 2000; Koch et al, 2001;
Ellison et al, 2005; Clifford et al, 2006; Thompson et al, 2006). To
date, only one study investigating APC mutational status in four
CNS PNET tumours has been reported, in which no mutations
were found (Koch et al, 2001).
A significant association between CTNNB1 nuclear immuno-
reactivity and survival has earlier been demonstrated in medullo-
blastoma, with nuclear accumulation being associated with a
favourable outcome (Ellison et al, 2005; Gajjar et al, 2006). This is
in contrast to other tumour types, such as colon, breast and
hepatocellular carcinomas, in which nuclear immunoreactivity has
been associated with disease progression and a poorer prognosis
(Lin et al, 2000; Inagawa et al, 2002; Bondi et al, 2004).
The aim of this study was to investigate the WNT/b-catenin
pathway in a set of CNS PNETs, using immunohistochemistry
(IHC) to determine the cellular location of CTNNB1. This serves as
a marker for pathway status, in which nuclear staining represents
the active state and cytoplasmic the inactive state (Eberhart et al,
2000). The pathway target CCND1 was also investigated by IHC
and results correlated with CTNNB1 localisation. MKI67 (antigen
identified by monoclonal antibody to Ki67) protein levels were
investigated to measure cell proliferation rates and compared with
CTNNB1 and CCND1 data. The mutational status of exon 3 of
CTNNB1 and the mutation cluster region of APC were investigated
by sequencing and correlated with the IHC results. The pathway
status was also investigated in a set of medulloblastomas for
comparison. Results were correlated with clinical information.
MATERIALS AND METHODS
Sample information
Tumour samples were obtained from the Children’s Cancer and
Leukaemia Group (CCLG) and the Cooperative Human Tissue
Network (CHTN). A total of 25 snap-frozen CNS PNETs, all located
in the cerebral hemispheres, and 22 medulloblastomas were
obtained. Five CNS PNETs were recurrences, four with the paired
primary. Two medulloblastomas were recurrences and one was
paired. Eight pineoblastomas were also obtained, six were primary
and two were recurrences (unpaired). Of the primary medullo-
blastomas, 85% were classical, 10% desmoplastic and 5%
anaplastic. The recurrent tumours included one classical and one
desmoplastic tumour. Medulloblastoma subtypes were assigned
according to the WHO criteria (Louis et al, 2007). Two CNS PNETs
and four pineoblastomas were obtained from CHTN. All other
tumours were obtained from CCLG. When cutting a piece of frozen
tissue for analysis, a small piece was taken and smeared along a
slide, which was subsequently stained with haematoxylin and eosin
to determine whether the tissue contained tumour cells.
Forty-two CNS PNETs (all cerebral), 46 medulloblastoma and
seven pineoblastoma samples were fixed in 4% phosphate buffered
formaldehyde and embedded in paraffin. Seven CNS PNETs were
recurrences, five with the paired primary. Three medulloblastomas
were recurrent tumours, one paired and two not paired. Of the
primary medulloblastomas, 44% were classical, 33% desmoplastic,
14% anaplastic, 7% large cell and one medullomyoblastoma. The
recurrent tumours included one classical, one anaplastic and one
medullomyoblastoma. Blood samples were received for five CNS
PNETs, three medulloblastomas and two pineoblastomas. All
paraffin tumour samples were obtained from CCLG.
Pineoblastomas were included in the study because of their
histopathological similarities to other CNS PNETs (Louis et al,
2007). In the UK, pineoblastomas are also treated with protocols
similar to CNS PNETs (Pizer et al, 2006). For analysis they were
included in the CNS PNET cohort.
Clinical information, including gender, age at diagnosis, time
to recurrence, date of death or last follow-up if still alive and
metastatic status (using the Chang staging system (Chang et al,
1969)), was obtained from CCLG and CHTN. Multiple Centre
Research Ethics Committee approval was obtained for the study.
Consent for use of tumour samples was taken in accordance with
national tumour banking procedures and the human tissue act.
Immunohistochemistry
Formalin fixed paraffin-embedded (FFPE) samples were analysed
on a tissue microarray (TMA). After review by a pathologist,
representative areas of tumour tissue were selected. Three cores
from each tumour, taken from different locations in the section,
were included on the array. Immunohistochemistry was carried
out as described earlier (Ridley et al, 2008). Slides were incubated
with either CTNNB1 (1:500, Cell Signalling Technology, Hitchin,
UK), CCND1 (1:100, Abcam, Cambridge, UK) or MKI67 (MIB-1
clone, 1:50, Dako, Ely, UK).
Results for CTNNB1 were scored by location, either as nuclear
(pathway active), cytoplasmic or negative (pathway inactive).
Samples displaying nuclear staining were divided into two groups
depending on the percentage of positive nuclei. Those with less
than 10% of nuclei-positive were labelled as ‘low’ and those with
greater than 10% as ‘high’. CCND1 and MKI67 were scored by
calculating the percentage of positive cells. A total of 100 cells were
counted in five randomly chosen fields of view. CCND1 was
considered to be overexpressed if greater than 10% of cells were
positive. Lost cores or those in which the majority of tissue was
necrotic were removed from the analysis.
Mutational analysis
DNA was extracted from 25 snap-frozen CNS PNETs, 22
medulloblastomas and eight pineoblastomas. The pineoblastoma
samples were included in the CNS PNET cohort for analysis.
Constitutional DNA from five blood samples from CNS PNET
patients, three from medulloblastoma and two from pineoblastoma
patients was also extracted. A total of 5–10mg of tissue was lysed
in lysis buffer (50mM Tris pH 8, 100mM EDTA pH 8, 100mM NaCl
and 1% SDS) and proteinase K (20mgml
 1)a t3 7 1C overnight.
DNA was obtained by phenol:chloroform extraction followed by
isopropanol precipitation. Standard PCR reactions were carried
out using earlier published primers designed to amplify exon 3 of
CTNNB1 (Genbank accession number X89579) (Koch et al, 1999).
A combination of published (Huang et al, 2000) and newly
designed primers (50 primer sequence TGCCACTTGCAAAGT
TTCTTC, 30 primer sequence CATTCCACTGCATGGTTCAC,
annealing temperature 601C) were used to amplify the mutation
cluster region of APC (Genbank accession number NM000038).
PCR products were purified by incubation with 0.3U shrimp
alkaline phosphatase (Promega, Southampton, UK) and 1.5U
exonuclease I (NEB, Hitchin, UK) at 371C for 8min followed by
15min at 721C. Sequencing reactions were performed on 1ml
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spurified PCR product using Big Dye V1.1 (Applied Biosystems,
Warrington, UK), following the manufacturer’s protocol.
Statistical analysis
Association between clinical factors and immunohistochemical
status was investigated using the Fisher’s Exact Test. Overall and
progression-free survival were investigated using the Kaplan–
Meier method. The differences were estimated using the log-rank
(Mantel-Cox) test. Overall survival was defined as the time between
date of original diagnosis and date of death. Progression-free
survival was defined as the time between date of original diagnosis
and date of first event (recurrence or death). Patients still alive at
the end of the study were censored at the date of last follow-up.
Median survival was estimated using Kaplan–Meier method.
RESULTS
Clinical characteristics
In total, the frozen and FFPE samples represented 43 patients with
CNS PNET, 12 with pineoblastoma and 62 with medulloblastoma.
The CNS PNETs and pineoblastomas were analysed as one cohort
(CNS PNET cohort). The clinical characteristics of the two cohorts
are summarised in Table 1. Age at diagnosis, sex, relapse,
metastatic status, resection and treatment status were analysed
for an association with survival in both cohorts. In the CNS PNET,
cohort patients under 5 years had a significantly worse prognosis
than the rest of the cohort (overall survival, P¼0.045) (Figure 1A).
Patients who had a complete rather than partial resection had a
significantly better outcome (overall survival, P¼0.01)
(Figure 1B). Patients who were treated with both chemotherapy
and radiotherapy had a better overall survival and significantly
better progression-free survival (P¼0.01) (Figure 1C). No other
factors were significant in the CNS PNET cohort. In the
medulloblastoma cohort age at diagnosis, relapse, metastatic
status and treatment were significantly associated with survival.
Patients under 5 years had a worse prognosis (overall survival,
P¼0.006) (Figure 1D). Patients who had relapsed (overall
survival, Po0.001) or metastasised (overall survival, P¼0.01) also
had a poorer outcome (Figure 1E and F). Patients who had either
radiotherapy or chemotherapy and radiotherapy had a better
outcome (overall survival, Po0.001) (Figure 1G).
CTNNB1 immunohistochemistry
The cellular location of CTNNB1 was investigated in 49 tumours in
the CNS PNET cohort (including 7 pineal tumours), which
included 42 primary samples. Of 28 scorable primary CNS PNETs
10 displayed CTNNB1 nuclear staining (36%), which included one
pineal tumour (out of five) (Table 2). Two patterns of nuclear
staining were noted. In the first, only a small number of nuclei
were positive for CTNNB1. In the second, a large number of nuclei
were positive for CTNNB1 across the majority of the tissue
analysed. For scoring, the groups were defined by the percentage of
CTNNB1-positive nuclei, with the low nuclear group containing
less than 10% of positive nuclei and the high nuclear group
containing greater than 10% of positive nuclei. Six samples
displayed high CTNNB1 nuclear staining, with four having
greater than 30% of positive nuclei. In the other four (including
the pineoblastoma), low CTNNB1 nuclear positivity was seen
(Figure 2A and C). Cytoplasmic staining was seen in most tumours
with only one tumour negative. Seven recurrences were also
analysed, with six producing scorable results. Three displayed high
CTNNB1 nuclear staining and three cytoplasmic staining. For two
of the recurrences, the primary sample from the same patient was
analysed. Both displayed the same staining patterns. Concordance
of results across all cores was seen for all samples except one, in
which low CTNNB1 nuclear staining was seen in only one core.
The sample was scored as low nuclear CTNNB1.
CTNNB1 cellular location was also investigated in 46 medullo-
blastomas, including 43 primary samples. A total of 10 out of 37
scorable primary medulloblastomas displayed CTNNB1 nuclear
staining (27%) (Table 2). The same pattern of high and low nuclear
staining as the CNS PNET cohort was observed. High CTNNB1
nuclear staining was seen for three tumours and focal high
CTNNB1 nuclear staining was seen for two tumours. All high
CTNNB1 nuclear tumours displayed less than 30% of nuclei
positive. Five tumours displayed low CTNNB1 nuclear positivity
(Figure 2B and D). Four tumours were negative, the rest displayed
cytoplasmic staining. A result for only one recurrent sample was
obtained, which was negative for CTNNB1. The primary sample
was not analysed. Concordance across all cores was seen for
all medulloblastomas except four. Two displayed low CTNNB1
nuclear staining in two cores and only cytoplasmic staining in the
other and were placed in the low CTNNB1 nuclear group. One
sample displayed focal high CTNNB1 nuclear staining in two out of
the three cores. In the other sample, focal high CTNNB1 staining
was seen in one out of the three cores. The latter two samples were
placed in the high CTNNB1 nuclear group.
Table 1 Clinical characteristics of CNS PNET (n¼55, including 12
pineoblastomas) and medulloblastoma (n¼62) patient cohorts
CNS PNET Medulloblastoma
Sex (male:female ratio) 1.1:1 2.6:1
Mean age at diagnosis (years) 5.9 (0.4–15.5
years)
7.2 (0–14.4 years)
Percentage of patients who have relapsed 45% 35%
Average time to relapse (years) 1.1 2.2
Metastatic status
a
M0 55% 60%
M1 4% 3%
M2 11% 5%
M3 15% 21%
M4 4% 3%
Unknown 13% 8%
Median survival (years) 1.8 5.3
Median progression-free survival (years) 0.8 4.1
Median follow-up for patients still alive
(years)
3.9 (n¼12) 6.5 (n¼28)
Resection
Partial 53% 48%
Complete 27% 40%
Unknown 20% 11%
Treatment
b
None 18% 3%
Chemotherapy 24% 19%
Radiotherapy 7% 10%
Chemotherapy and radiotherapy 40% 68%
Unknown 11% 0%
Medulloblastoma subtype
c
Classic — 56%
Desmoplastic — 24%
Anaplastic — 11%
Large cell — 5%
Medullomyoblastoma — 3%
Abbreviation: CNS PNET¼central nervous system primitive neuroectodermal
tumour.
aMetastatic stages according to Chang staging system (Chang et al, 1969).
bChemotherapy and radiotherapy was not uniform across all patients.
cAccording to
the WHO criteria (Louis et al, 2007).
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core loss or the presence of necrotic tissue, in both CNS PNET and
medulloblastoma cohorts. In the CNS PNET cohort, 28 primary
and six recurrent tumours were scorable and 14 primary plus
one recurrent tumour were unscorable. In the medulloblastoma
cohort, 37 primary and one recurrent tumour were scorable
and six primary plus two recurrent tumours were unscorable.
Clinical features of scorable and unscorable tumours were
examined to ensure there was no sampling bias (Supplementary
Tables 1 and 2).
CCND1 immunohistochemistry
CCND1 results were obtained for 27 primary tumours in the CNS
PNET cohort. Where positive, the protein was localised in the
nucleus. CCND1 was overexpressed in 12 samples (44%, no
pineoblastomas) with percentages of positive cells ranging from 11
to 56% (Figure 2E). Of the 10 tumours with nuclear CTNNB1, eight
(80%) displayed CCND1 overexpression, which included all
tumours with high CTNNB1 nuclear positivity. A total of 4 out
of 17 (24%) tumour samples displaying cytoplasmic or negative
CTNNB1 staining also overexpressed CCND1. Six recurrent
tumours were analysed, three with high CTNNB1 nuclear
staining and three with CTNNB1 cytoplasmic staining. All six
displayed CCND1 overexpression (Table 2). A significant correla-
tion was found between CTNNB1 nuclear positivity and CCND1
overexpression in the primary CNS PNETs (Fisher’s Exact Test,
P¼0.007).
In medulloblastoma, CCND1 overexpression (nuclear) was seen
in 4 out of 37 (11%) primary tumours with percentages of positive
cells ranging from 14 to 22%. This included 3 out of 10 (30%)
tumours with CTNNB1 nuclear staining, one with low and two with
a high level of staining. CCND1 was also overexpressed in 1 out of
27 (4%) tumours with cytoplasmic or negative CTNNB1 staining
(Table 2). An association between CTNNB1 nuclear staining and
CCND1 overexpression in the primary medulloblastomas just
below significance was identified (Fisher’s Exact Test, P¼0.052).
However, 70% of tumours with nuclear localisation of CTNNB1 did
not display CCND1 overexpression.
As for CTNNB1 IHC, a relatively high number of samples were
unscorable in the CCND1 analysis. For the CNS PNET cohort, one
additional sample was unscorable in the CCND1 analysis
compared with the CTNNB1 analysis. For medulloblastoma, the
unscorable samples were the same in both experiments. Therefore,
no new comparisons were made.
MKI67 immunohistochemistry
MKI67, a proliferation marker, was investigated to see if CCND1
overexpression was affecting cell proliferation. MKI67 results were
obtained for 18 primary and six recurrent tumours in the CNS
PNET cohort. The number of positive cells ranged from 0 to 42%
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CT(n=12)
CT+RT(n=42)
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Figure 1 Kaplan–Meier curves for analysis of the CNS PNET and medulloblastoma patient cohorts. A significant difference in overall survival was seen
between CNS PNET patients under the age of 5 years at diagnosis and those over 5 years (P¼0.045) (A). Patients who had a complete rather than partial
resection had a better prognosis (overall survival, P¼0.01) (B). CNS PNET patients treated with both chemotherapy (CT) and radiotherapy (RT) had a
significantly better progression-free survival (P¼0.01) (C). Medulloblastoma patients under 5 years at diagnosis also showed a significant association with
survival (overall survival, P¼0.006) (D). Medulloblastoma patients that had not relapsed (Po0.001) (E) or metastasised (overall survival, P¼0.01) (F) had a
significantly better prognosis. Medulloblastoma patients treated with either radiotherapy or chemotherapy and radiotherapy also had a better outcome
(overall survival, Po0.001) (G). All survival times are in months.
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Case
a Location Sex Histological subtype
b CTNNB1 IHC CCND1 IHC CTNNB1 mutation
c
SP01 Cerebral F   C+ W T
SP02 Cerebral F   C   WT
SP03 Cerebral F   C   WT
SP04 Cerebral M   C   WT
SP05 Cerebral M   C   WT
SP06 Cerebral F   C   WT
SP07 Pineal M   C   WT
SP08 Pineal F   C   WT
SP09 Cerebral F   C   No result
SP10 Pineal M   C   No result
SP11 Cerebral F   C   No result
SP12 Cerebral F   C No result No result
SP13 Cerebral F   C + No result
SP14 Cerebral F   O + No result
SP15 Cerebral F   C + No result
SP16 Pineal M   C   No result
SP17 Cerebral M   C   No result
SP18 Cerebral M   C   No result
SP19 Cerebral M   Nl o w + W T
SP20 Pineal M   Nl o w   No result
SP21 Cerebral F   N low + No result
SP22 Cerebral M   Nl o w   No result
SP23 Cerebral M   N high + No result
SP24 Cerebral M   N high + WT
SP25 Cerebral M   N high + WT
SP26 Cerebral F   N high + WT
SP27 Cerebral M   N high + No result
SP28 Cerebral M   N high + No result
SP01R Cerebral F   C + No result
SP29R Cerebral M   C+ W T
SP30R Cerebral F   C + No result
SP24R Cerebral M   N high + WT
SP31R Cerebral F   N high + No result
SP32R Cerebral M   N high + No result
MB01 Posterior fossa M Classical C   WT
MB02 Posterior fossa M Anaplastic C   WT
MB03 Posterior fossa F Desmoplastic C   WT
MB04 Posterior fossa M Classical C   WT
MB05 Posterior fossa F Classical C   No result
MB06 Posterior fossa F Classical C   No result
MB07 Posterior fossa M Anaplastic O   No result
MB08 Posterior fossa M Classical C   No result
MB09 Posterior fossa M Anaplastic O   No result
MB10 Posterior fossa F Classical C   No result
MB11 Posterior fossa M Desmoplastic C   No result
MB12 Posterior fossa M Anaplastic C   No result
MB13 Posterior fossa F Desmoplastic O   No result
MB14 Posterior fossa M Large cell C   No result
MB15 Posterior fossa M Anaplastic C   No result
MB16 Posterior fossa M Desmoplastic C   No result
MB17 Posterior fossa M Classical C   No result
MB18 Posterior fossa M Classical C   No result
MB19 Posterior fossa M Desmoplastic C   No result
MB20 Posterior fossa M Classical O + No result
MB21 Posterior fossa F Classical O   No result
MB22 Posterior fossa M Large cell C   No result
MB23 Posterior fossa M Classical C   No result
MB24 Posterior fossa M Desmoplastic C   No result
MB25 Posterior fossa M Desmoplastic C   No result
MB26 Posterior fossa F Desmoplastic C   No result
MB27 Posterior fossa M Anaplastic C   No result
MB28 Posterior fossa M Desmoplastic N low + No result
MB29 Posterior fossa M Desmoplastic N low   No result
MB30 Posterior fossa M Classical N low   No result
MB31 Posterior fossa M Medullomyoblastoma N low   No result
MB32 Posterior fossa M Desmoplastic N low   No result
MB33 Posterior fossa M Desmoplastic N high   No result
MB34 Posterior fossa F Classical N high   No result
MB35 Posterior fossa M Desmoplastic N high   No result
MB36 Posterior fossa M Large cell N high + No result
MB37 Posterior fossa M Desmoplastic N high + No result
MB38R Posterior fossa M Anaplastic O   No result
Abbreviations: C¼cytoplasmic staining; CNS PNET¼central nervous system primitive neuroectodermal tumour; IHC¼immunohistochemistry; N high¼high nuclear staining;
Nl o w¼low nuclear staining; MB¼medulloblastoma; O¼negative staining; WT¼wild type; +¼over expression;  ¼no expression.
aSP¼CNS PNET. R indicates a recurrent
sample. Primary and recurrent samples with the same case number indicate that samples are from the same patient.
bHistological subtype is only included for medulloblastoma
samples, according to the WHO criteria (Louis et al, 2007).
cAdditional samples were sequenced that were not included in the immunohistochemistry cohorts.
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s(Figure 2F). No correlation was found between MKI67 results and
CCND1, or CTNNB1 localisation.
MKI67 results were obtained for 34 primary medulloblastomas
and one recurrence. The number of positive cells ranged from 0 to
40%. No correlation was found between MKI67 results and
CCND1, or CTNNB1 localisation.
The clinical features of the scorable and unscorable samples in
the CNS PNET cohort were compared to check for sampling bias,
with none found (Supplementary Table 3). The scorable and
unscorable samples in the medulloblastoma cohort were very
similar to the CTNNB1 and CCND1 analyses; therefore, no new
comparison was made.
Sequencing
In the CNS PNET cohort, only one of the 26 primary tumours
sequenced contained a mutation in exon 3 of CTNNB1 (4%)
(Figure 3). No mutations were found in six recurrent samples.
The mutation was a missense point mutation at codon 34
(GGA4CGA), converting glycine to arginine. No blood samples
contained mutations. The matching blood sample for the tumour
containing a mutation was not available for sequencing. An IHC
result for the CNS PNET sample, for which a mutation in CTNNB1
was found, was not obtained from the TMA due to core drop out.
However, high CTNNB1 nuclear staining was seen in a separate
experiment (Figure 2G). Four other primary and one recurrent
tumour that displayed CTNNB1 nuclear staining were sequenced
and none contained mutations (Table 2).
Four out of 20 primary medulloblastomas contained CTNNB1
mutations (20%) (Figure 3). Four recurrent samples were
sequenced with none containing mutations. All mutations were
missense point mutations; one at codon 32 (GAC4TAC),
converting aspartic acid to tyrosine; two at codon 33 (TCT4TGT),
converting serine to cystine; and one at codon 34 (GGA4GAA),
converting glycine to glutamic acid. One sample with a mutation at
codon 33 also contained a missense point mutation at codon 40
(ACT4AGT), converting threonine to serine. No blood samples
contained mutations. No blood samples from patients with
mutations in their tumours were sequenced. There was only a
small overlap in the cohorts of medulloblastoma samples analysed
200 m 200 m 200 m
200 m 200 m 200 m
200 m
Figure 2 Immunohistochemical analysis of CTNNB1, CCND1 and MKI67 in the CNS PNET and medulloblastoma cohorts. Two patterns of CTNNB1
nuclear staining were seen in both CNS PNETs and medulloblastomas. A low level of nuclear staining (less than 10%) was seen in some CNS PNETs
(A) and medulloblastomas (B). In others a high level of nuclear staining (greater than 10%) was seen (C CNS PNET and D medulloblastoma). Over
expression of CCND1 was also seen in a subset of tumours (E, CNS PNET). MKI67 levels were measured in both cohorts (F, CNS PNET). Levels did not
correlate with CCND1. An additional CNS PNET sample containing a mutation in CTNNB1 exon 3 was analysed in a separate experiment and displayed
high CTNNB1 nuclear staining (G).
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sby IHC and sequencing. Therefore, none of the samples displaying
CTNNB1 nuclear staining were sequenced and no IHC result was
obtained for any of the tumours containing mutations (Table 2).
No mutations were found in the mutation cluster region of APC
in 20 CNS PNET and 19 medulloblastoma primary tumours
sequenced. None of the blood samples, from both tumour types,
contained APC mutations.
Clinical correlates
In the CNS PNET cohort, CTNNB1 nuclear cases contained a
higher proportion of males (male: female ratio 4:1 compared with
0.6:1 in non-nuclear), and displayed a higher 5-year survival rate
(30% compared with 13%) than the non-nuclear cases. However,
no significant association was seen for any clinical factor tested
(Fisher’s Exact Test). Analysis could be limited by the small sample
size (n¼28).
Comparison of all CNS PNET CTNNB1 nuclear cases with non-
nuclear cases did not reveal a significant difference in overall or
progression-free survival (P¼0.852 and 0.536, respectively)
(Figure 4A). However, comparison of high CTNNB1 nuclear cases
to all other tumours (low CTNNB1 nuclear plus cytoplasmic and
negative cases), although not significant (overall survival,
P¼0.113), suggested a trend towards the association of high
CTNNB1 nuclear staining with a more favourable outcome
(Figure 4B). Comparison of cases with high CTNNB1 nuclear
staining to just those with a low level of nuclear staining did reveal
a significant difference in overall survival (P¼0.007) (Figure 4C).
However, only limited conclusions can be drawn because of the
small number of samples analysed (n¼10). The results were
supported by the 5-year overall survival rates. Patients with a high
level of CTNNB1 nuclear staining had a 5-year overall survival rate
of 50% compared with 11% for the rest of the cohort.
In the medulloblastoma cohort, association between CTNNB1
nuclear immunoreactivity and percentage of cases that had
relapsed almost reached significance (Fisher’s exact test,
P¼0.056) with a lower percentage of relapses seen in the nuclear
cases. Although not significant, there was a male bias in the
CTNNB1 nuclear cases (male: female ratio 9:1 compared with
2.9:1). A total of 60% of CTNNB1 nuclear cases were desmoplastic
compared with 31% of non-nuclear tumours. CTNNB1 nuclear
immunoreactivity was not significantly linked to overall or
progression-free survival (P¼0.590 and 0.517, respectively).
However, the Kaplan–Meier curves suggest a difference
(Figure 4D). This was also reflected in the overall survival rates.
At 5 years, 56% of patients with CTNNB1 nuclear staining and 46%
of patients with only cytoplasmic or negative staining were still
alive. At 10 years, the difference between survival rates was greater
with 56% of CTNNB1 nuclear patients still alive and 24% of those
with only cytoplasmic or negative staining. It is possible that
significance was not reached because of the relatively small sample
size in this study (n¼37). Comparison of cases displaying a high
level of CTNNB1 nuclear positivity to the rest of the cohort was not
significant (overall survival, P¼0.310), but suggested a better
survival for the high nuclear group (Figure 4E). This was
supported by the difference in 5-year overall survival rates of
80% for patients with high CTNNB1 nuclear staining compared
with 44% for the rest of the cohort.
DISCUSSION
This study is the first to extensively investigate the status of
the WNT/b-catenin pathway in CNS PNETs and has shown
pathway activation in a high proportion of tumours (36%), as well
as suggested a link between pathway activation and a more
favourable outcome. The high percentage of tumours displaying
activation suggests that the pathway plays an important role in the
pathogenesis of CNS PNETs and is a potential target for future
therapies. Further investigation is needed to validate findings and
understand the biological role the pathway is playing in
tumourigenesis. An equivalent rate of pathway activation was
seen in the medulloblastomas investigated in this study (27%), in
agreement with earlier research (Eberhart et al, 2000; Yokota et al,
2002; Ellison et al, 2005). Although a different CTNNB1 antibody
was used in these studies (BD Transduction Laboratories, San Jose,
CA, USA) the agreement in the results suggests the two alternative
antibodies are comparable.
Nuclear localisation of CTNNB1 was used to determine pathway
activation. The results were supported by the significant corre-
lation with CCND1 overexpression in both cohorts. CCND1 has
earlier been shown to be a target of the WNT/b-catenin pathway
(Tetsu and McCormick, 1999). The evidence, although significant,
was not as strong in the medulloblastoma cohort, with 70% of
tumours displaying nuclear localisation of CTNNB1 showing no
CCND1 overexpression. This included three out of five tumours
with high nuclear CTNNB1 expression. Correlation of CCND1
overexpression and CTNNB1 nuclear localisation was not absolute
in either cohort, with some tumours displaying only cytoplasmic
or negative CTNNB1 staining overexpressing CCND1. This could
suggest that an alternative factor is influencing CCND1 over-
expression. CCND1 expression has been increased in other tumour
types by gene amplification or translocation, or controlled by
alternative cell signalling pathways such as the sonic hedgehog
pathway (Fu et al, 2004; Marino, 2005). However, the significant
correlation with CTNNB1 nuclear localisation found particularly in
the CNS PNET cohort, strongly suggests that the WNT/b-catenin
pathway is increasing CCND1 expression in the tumours with
pathway activation in this study.
The correlation between CTNNB1 nuclear localisation and
CCND1 overexpression suggests that WNT/b-catenin pathway
activation is affecting cell proliferation. However, no correlation
was found between CCND1 and MKI67 in either cohort. It may be
that WNT/b-catenin pathway activation is not affecting cell
proliferation or that alternative mechanisms are affecting the
proliferation rate in tumours without pathway activation therefore
masking any correlation that could be found.
Unlike medulloblastomas, pathway activation in CNS PNETs
does not seem to be caused by mutations in exon 3 of CTNNB1,
with only one CNS PNET in this study containing a mutation. This
A-A-V-S-H-W-Q-Q-Q-S-Y-L-D-S-G-I-H-S-G-A-T-T-T-A-P-S-L-S-G-K-G-N-P-E-E-E-V-D-T-T
S C Y
E
R
Codon 20 60
Exon 3
Figure 3 Schematic representation of mutation locations in exon 3 of CTNNB1. Amino acid substitutions are indicated above the sequence; grey changes
represent mutations from medulloblastoma and black from CNS PNET.
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stumour did display high nuclear staining of CTNNB1, suggesting
that the mutation could be the cause of pathway activation in this
sample. The overlap in the cohorts used for IHC and sequencing
was relatively low. Results for both methods were only obtained for
12 primary and two recurrent samples. This included four primary
and one recurrent tumour with CTNNB1 nuclear staining. Six
additional primary and two recurrent tumours with CTNNB1
nuclear staining were not sequenced. Therefore, no definite
conclusions can be drawn about whether there is a correlation
between CTNNB1 mutation and nuclear staining. However,
only one mutation was found in 32 tumours sequenced, which
included 17 tumours with no IHC result, and therefore no
known WNT/b-catenin pathway status, suggesting CTNNB1 exon
3 mutation to be rare.
Only four medulloblastomas had both IHC and sequencing
results, all displaying cytoplasmic CTNNB1 staining and contain-
ing no mutations in CTNNB1 exon 3. Therefore, it cannot be
concluded whether there is a correlation between nuclear staining
and mutation of CTNNB1. However, the overall mutation rate
identified (20%) was similar to those found earlier in which a
correlation was reported, suggesting that this is likely to be the
case in this study (Ellison et al, 2005; Clifford et al, 2006;
Thompson et al, 2006).
Matching blood samples were not available for any of the CNS
PNET or medulloblastoma tumours containing mutations there-
fore it is not known whether these are somatic or constitutional.
The mutations detected in the medulloblastomas are consistent
with those described in earlier studies (Eberhart et al, 2000; Koch
et al, 2001; Yokota et al, 2002; Ellison et al, 2005; Clifford et al,
2006; Thompson et al, 2006). The mutation in the single CNS
PNET identified here is in the same codon as one of the
medulloblastomas and a CNS PNET in an earlier study, in which
a missense point mutation caused a glycine to valine substitution
(Koch et al, 2001). The substitution of glycine to arginine, found
in the CNS PNET in this study, has not been seen in CNS
PNETs before, but has been found in medulloblastoma and
pancreatic tumours (Abraham et al, 2002; Haberler et al, 2008). All
the mutations altered residues that are phosphorylation sites for
GSK-3b (codon 33), or are adjacent residues (codons 32, 34 and
40). These are predicted to prevent phosphorylation of CTNNB1 by
GSK-3b, and therefore prevent its degradation.
In colon cancer, the WNT pathway is commonly activated by
mutations in the mutation cluster region of APC. However, no
mutations were found in this region in the CNS PNET or
medulloblastoma cohorts. Further investigation to determine the
molecular basis of pathway activation is needed to help understand
if it is playing a role in disease development. It is possible that
mutations are present in other regions of the CTNNB1 or APC
genes not investigated in this study. Alternative factors that could
cause pathway activation in CNS PNETs include inactivating
mutations in the pathway inhibitors AXIN1 and AXIN2. Mutations
have been identified in both genes in different tumour types
including medulloblastoma, hepatocellular and colon carcinoma
(Liu et al, 2000; Satoh et al, 2000; Taniguchi et al, 2002; Baeza et al,
2003; Koch et al, 2007). WNT ligands or their receptors could also
be overexpressed. Earlier studies have identified increased
expression of WNT and frizzled receptor genes in different
tumour types (Huguet et al, 1994; Janssens et al, 2004; Merle
et al, 2004). Epigenetic alterations have also been identified,
including inactivation of secreted frizzled-related protein genes
in colorectal cancer (Suzuki et al, 2004). Interaction of WNT/b-
catenin signalling with other signalling pathways has been shown
to affect the levels of signalling as well (Moon et al, 2002; Saldanha
et al, 2004).
Although not statistically significant, survival analysis in the
CNS PNET cohort suggested a trend towards a better prognosis for
patients whose tumours displayed high CTNNB1 nuclear staining.
Significance was achieved when high CTNNB1 nuclear tumours
were compared with low CTNNB1 nuclear tumours, but was
limited by the very small number of samples included in the
analysis. Together with the differences in 5-year overall survival
rates, the data suggested that a higher level of pathway activation
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Figure 4 Kaplan–Meier curves for analysis of CTNNB1 IHC. Comparison of CNS PNETs displaying nuclear CTNNB1 with non-nuclear staining did not
reveal a significant difference in overall survival (P¼0.852) (A). Comparison of high CTNNB1 nuclear tumours (high nuclear) with the rest of the cohort
(rest; tumours displaying low nuclear, cytoplasmic or negative staining), although not statistically significant (overall survival, P¼0.113), suggested a trend
towards a better prognosis for the high CTNNB1 nuclear group (B). A significant difference in overall survival was seen between CNS PNETs displaying high
and low CTNNB1 nuclear staining (overall survival, P¼0.007) (C). In the medulloblastoma cohort comparison of nuclear with non-nuclear CTNNB1
tumours was not significant (overall survival, P¼0.590), but suggested a trend towards better survival for the nuclear group (D). Comparison of CTNNB1
high nuclear cases (high nuclear) with all other tumours in the medulloblastoma cohort (rest) also suggested the same trend (overall survival, P¼0.310)
(E). All survival times are in months.
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swas linked to a better outcome and is in agreement with the
association of better prognosis with WNT/b-catenin pathway
activation earlier found in medulloblastoma (Ellison et al, 2005;
Gajjar et al, 2006). The number of samples included in this analysis
was relatively low; therefore, further investigation is needed for
confirmation of results.
No significant association was found for medulloblastomas in
this study between pathway activation and survival. However, the
Kaplan–Meier curves and overall survival rates suggest a trend
towards better survival for patients with the pathway active in their
tumours. Other clinical factors also suggest this, including the
higher percentage of relapses in non-nuclear cases. Significance
would need to be examined in a larger cohort.
Association of pathway activation with a favourable prognosis is
somewhat surprising, considering its link to a poorer outcome and
disease progression in other tumour types, including colon,
hepatocellular and breast carcinoma (Lin et al, 2000; Inagawa
et al, 2002; Bondi et al, 2004). However, an association with a
better prognosis has been seen before in medulloblastoma and
other tumour types such as non-small cell lung carcinoma and
ovarian cancer (Hommura et al, 2002; Catasus et al, 2004; Ellison
et al, 2005; Gajjar et al, 2006). There could be a number of reasons
for this link in CNS PNET and medulloblastoma. Pathway
activation could represent a subset of tumours with a less
aggressive phenotype than other subtypes. Activation of the
WNT/b-catenin pathway can have many different effects on a cell,
including influencing proliferation, apoptosis and differentiation.
Therefore, pathway activation could be causing a deleterious effect
such as promoting apoptosis. Alternatively, pathway activation
could affect sensitivity to treatment. A recent study in medullo-
blastoma cell lines demonstrated activation of the pathway after
irradiation (Salaroli et al, 2008). The high proportion of tumours
displaying pathway activation in both CNS PNET and medullo-
blastoma suggest that it could be an important treatment target.
However, the reason for the association with favourable prognosis
needs to be understood before strategies for targeting the pathway
are developed.
A high proportion of the medulloblastomas displaying nuclear
CTNNB1 staining were of the desmoplastic subtype, which differs
from earlier results (Thompson et al, 2006). Desmoplastic tumours
have been associated with a better survival than the classic
subtype, which might suggest this is the cause of better prognosis
in the nuclear positive cases in this study (Sure et al, 1995). No
statistically significant association between desmoplastic cases and
survival was found in this study. However, median survival for
desmoplastic cases was greater than the rest of the cohort (12 vs 2
years), suggesting that the lack of statistical significance may be
because of the small sample size (n¼37). Median survival for
desmoplastic cases with nuclear CTNNB1 staining was greater
than desmoplastic cases with only cytoplasmic or negative staining
(7 vs 3.5 years). Although not significant, this data suggests that
tumour subtype was not the cause of better prognosis for the
CTNNB1 nuclear tumours. The most comprehensive analysis of
WNT status and survival in medulloblastomas did not include any
desmoplastic tumours (Ellison et al, 2005). The results from this
study suggest that future cohorts investigated should include this
tumour subtype. It is interesting to note that all the medullo-
blastomas that contained mutations were of the classical subtype.
However, only 10% of the samples sequenced were desmoplastic.
Association between WNT/b-catenin pathway activation and
chromosome 6 loss has earlier been found in medulloblastoma
(Clifford et al, 2006; Thompson et al, 2006). Copy number data
generated from Affymetrix SNP chip (Affymetrix, Santa Clara, CA,
USA) analysis for 12 of the CNS PNETs used in this study (six
nuclear and six cytoplasmic CTNNB1) suggest that this is not the
case for this tumour type. Only one tumour displaying cytoplasmic
CTNNB1 staining had a loss of one copy of chromosome 6 (S
Miller, unpublished data).
In summary, the WNT/b-catenin pathway has been found to be
active in over one-third of CNS PNETs, suggesting that it plays an
important role in the pathogenesis of this tumour type. The
percentage of samples displaying pathway activation is similar to
results seen in medulloblastoma. However, the method of
activation seems to differ from mutation of exon 3 of CTNNB1.
The data has also revealed a potential link between survival and the
extent of pathway activation in CNS PNETs. Further investigation
involving a larger cohort is now needed to determine this. The
mechanism of activation, as well as the role the pathway is playing
in the pathogenesis of these tumours also needs to be determined
to better understand their biology, as well as help to decide how
the pathway could be targeted as a part of future treatment
strategies.
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